TriangleAmivantamab (NCT07586202)
Amivantamab trial for Carcinoma, Non-Small-Cell Lung (NCT07586202). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with previously untreated, removable stage II through IIIB N2 nonsquamous lung cancer carrying an EGFR exon-19 deletion or L858R mutation. Complete surgery must be feasible.
The idea: give amivantamab before surgery with either lazertinib or carboplatin plus pemetrexed. Amivantamab blocks EGFR and MET growth signals; lazertinib blocks mutant EGFR. Researchers examine removed tissue to see how much viable cancer remains and assess safety. Groups are nonrandomized. Biopsy may be needed if stored tissue is inadequate.
This phase 2 study plans 68 patients. Janssen sponsors four recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.